PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide:: First results in patients with meningiomas

被引:0
|
作者
Henze, M
Schuhmacher, J
Hipp, P
Kowalski, J
Becker, DW
Doll, J
Mäcke, HR
Hofmann, M
Debus, J
Haberkorn, U
机构
[1] Univ Heidelberg, Dept Nucl Med, D-69120 Heidelberg, Germany
[2] German Canc Res Ctr, D-6900 Heidelberg, Germany
[3] Univ Basel Hosp, CH-4031 Basel, Switzerland
[4] Hannover Med Sch, D-3000 Hannover, Germany
关键词
somatostatin receptors; DOTATOC; Ga-68; PET; meningioma;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Imaging of somatostatin receptors (SSTRs) using [In-111]diethylenetriaminepentaacetic-acid-octreotide (DTPAOC) has proven to be helpful in the differentiation of meningiomas, neurinomas or neurofibromas, and metastases as well as in the follow-up of meningiomas, A drawback of the SPECT method is its limited sensitivity in detecting small meningiomas. Because of PET's increased spatial resolution and its ability to absolutely quantify biodistribution, a PET tracer for SSTR imaging would be desirable. Methods: 1,4,7,10-tetraazacyclododecane-N,N ' ,N "N ' ' ' -tetraacetic-acid-D-Phe(1)-Tyr(3)-octreotide (DOTATOC) was labeled using the positron-emitting generator nuclide Ga-68. We acquired dynamic PET images over 120 min after intravenous injection of 175 MBq [Ga-68]DOTATOC in 3 patients suffering from 8 meningiomas (WHO I-o; 7- to 25-mm diameter). Patients' heads had been fixed using individually shaped fiber masks equipped with an external stereotactic localizer system to match PET, CT, and MRI datasets. Results: [68Ga]DOTATOC was rapidly cleared from the blood (half-life alpha, 3.5 min; half-life beta, 63 min). Standardized uptake values (SUVs) of meningiomas increased immediately after injection and reached a plateau 60-120 min after injection (mean SUV, 10.6). No tracer could be found in the surrounding healthy brain tissue. AH meningiomas (even the 3 smallest [7- to 8-mm diameter]) showed high tracer uptake and could be visualized clearly. Tracer boundaries showed a good correspondence with the matched CT and MRI images. PET provided valuable additional information regarding the extent of meningiomas located beneath osseous structures, especially at the base of the skull. Conclusion: According to our initial experiences, [Ga-68]DOTATOC seems to be a very promising new PET tracer for imaging SSTRs even in small meningiomas, offering excellent imaging properties and a very high tumor-to-background ratio.
引用
收藏
页码:1053 / 1056
页数:4
相关论文
共 50 条
  • [31] Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide:: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide
    Bangard, M
    Béhé, M
    Guhlke, S
    Otte, R
    Bender, H
    Maecke, HR
    Biersack, HJ
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (06) : 628 - 637
  • [32] Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy
    Putzer, Daniel
    Gabriel, Michael
    Henninger, Benjamin
    Kendler, Dorota
    Uprimny, Christian
    Dobrozemsky, Georg
    Decristoforo, Clemens
    Bale, Reto Josef
    Jaschke, Werner
    Virgolini, Irene Johanna
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (08) : 1214 - 1221
  • [33] DOTA-D-Phe(1)-Tyr(3)-octreotide (DOTATOC) a unique somatostatin receptor ligand for labeling with a variety of metallic radionuklides.
    Macke, HR
    Behe, M
    Froidevaux, S
    Heppeler, A
    Jermann, E
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 57 - 57
  • [34] [18F]AlF-NOTA- octreotide vs. [68Ga]Ga-DOTA-somatostatin analogue PET in neuroendocrine tumour patients: final results of a prospective multicentre trial
    Pauwels, E.
    Cleeren, F.
    Tshibangu, T.
    Koole, M.
    Serdons, K.
    Boeckxstaens, L.
    Dekervel, J.
    Vandamme, T.
    Lybaert, W.
    Van den Broeck, B.
    Clement, P. M.
    Geboes, K.
    Van Cutsem, E.
    Stroobants, S.
    Verslype, C.
    Bormans, G.
    Deroose, C. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S179 - S180
  • [35] Somatostatin receptor based PET/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically suspected insulinoma
    Sharma, Punit
    Arora, Saurabh
    Karunanithi, Sellam
    Khadgawat, Rajesh
    Durgapal, Prashant
    Sharma, Raju
    Kandasamy, Devasenathipathy
    Bal, Chandrasekhar
    Kumar, Rakesh
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 60 (01): : 69 - 76
  • [36] An intraindividual comparison of target volume definition for radiation therapy based on contrast-enhanced MRI, -O-(2-[18F]-fluoroethyl)-L-tyrosine (FET)- and [68Ga]-DOTA-D Phe 1-3Tyr3-Octreotide (DOTATOC)-PET in 21 patients with meningiomas - final results
    Dittmar, J. O.
    Giesel, F.
    Kratochwill, K.
    Christmann, A.
    Welzel, T.
    Habermehl, D.
    Rieken, S.
    Haberkorn, U.
    Debus, J.
    Combs, S.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2013, 189 : 102 - 102
  • [37] 68Ga-DOTA-Tyr3-Octreotide PET in thyroid cancer patients compared to 18F-FDG-PET and radioiodine-avidity
    Putzer, D.
    Kross, A.
    Gabriel, M.
    Kendler, D.
    Dobrozemsky, G.
    Bale, R.
    Warwitz, B.
    vonGuggenberg, E.
    Virgolini, I. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S214 - S214
  • [38] Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-d-Phel-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide
    C. Decristoforo
    W. Cholewinski
    E. Donnemiller
    G. Riccabona
    R. Moncayo
    S.J. Mather
    European Journal of Nuclear Medicine, 2000, 27 : 1580 - 1580
  • [39] Treatment with long acting octreotide does not reduce tumor uptake of 68Ga[DOTA0, Tyr3]octreotate in patients with neuroendocrine tumors
    Haug, Alexander
    Rist, Carsten
    Bartenstein, Peter
    Hacker, Marcus
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [40] Comparison of 68Ga-DOTA-Tyr3-Octreotide PET and 18F-FDG PET in correlation to radioiodine-avidity in thyroid cancer patients
    Putzer, Daniel
    Gabriel, Michael
    Kroiss, Alexander
    Kendler, Dorota
    Bale, Reto
    Oberladstaetter, Michael
    Virgolini, Irene
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52